Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yantai CIPU Bioengineering is a Chinese biotechnology company specializing in the research, development, and clinical application of stem cell therapies. The company focuses on the isolation, purification, and large-scale expansion of mesenchymal stem cells (MSCs) derived from various sources, including umbilical cord and adipose tissue. Their therapeutic pipeline targets a broad range of conditions such as liver cirrhosis, diabetes, and degenerative joint diseases. CIPU operates advanced laboratory facilities and biobanking services to support regenerative medicine initiatives in the Shandong province and beyond.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yantai Bioengineering.